Dr Antonio Giordano has been an internationally recognized researcher specializing in the genetics of cancer and gene therapy for over 20 years. Dr Giordano is best known for his discovery of Rb2/p130, a tumorsuppressor gene, which has been found to be active in lung, endometrial, brain, breast, liver and ovarian cancers. In addition to this cancer suppressing gene, Dr Giordano discovered the protein p60, later named cyclin A, a substance that regulates growth in the cell cycle; CDK9 and CDK10, guardians of the human genome; as well as another cancer-related gene called NSP. Research has subsequently shown that CDK9 plays a critical role in cell differentiation, particularly in muscles; HIV transcription; and the inception of tumors. Through pursuit of basic research in molecular cancer biology, cancer progression, and novel therapies, his hope is to develop new molecular therapeutics and better diagnostic approaches for a variety of cancers and other diseases. Dr Giordano's work has received a number of international awards and he has published over 250 papers on his work in the fields of the cell cycle, gene therapy and the genetics of cancer. Dr Wen-Hwa Lee is, among his many accomplishments, renowned for identifying the first human tumorsuppressor gene, retinoblastoma susceptibility gene (RB), which plays a vital role in the cellular battle against cancer. In the late 1980s, his lab and others cloned the RB gene and demonstrated that the reconstitution of the wild-type RB suppressed tumor growth. RB represented a new class of gene that suppressed the growth of tumors, and since then, it has rapidly become a focus of major interest among cancer researchers. In addition to this pioneering research, his laboratory has linked two breast cancer susceptibility genes, BRCA-1 and BRCA-2, to the process of DNA repair. Dr Lee then proceeded to investigate the mechanism of these tumor suppressors in the maintenance of cell homeostasis and genomic stability. Via this research, he has further discovered and characterized more than a dozen of new genes. Today, Dr Lee's work continues to be primarily in the areas of molecular cancer genetics, mainly specializing in the mechanism of tumor suppressor gene functions, 
